Alimera Sciences, Inc. (ASZ1.F)
| Previous close | 3.0600 |
| Open | 2.9300 |
| Bid | 3.2100 x N/A |
| Ask | 3.3400 x N/A |
| Day's range | 2.9300 - 3.2150 |
| 52-week range | 1.4400 - 3.8300 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 169.91M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7900 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.83 |
GlobeNewswireAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of (i) Mr. Todd Wood as President of U.S. Operations of the Company, (ii) Mr. Elliot Maltz as Chief Financial
- GlobeNewswire
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’
Insider MonkeyAlimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript March 7, 2024 Alimera Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth […]
